R-Pharm turned out to be an investor in the development of a vaccine against COVID-19 from Moscow State University :: Society :: RBC

0
1


The question lies in the civil-legal plane, the ownership depends on the specific contract, confirms Ravil Niyazov, an expert at the Center for Scientific Consulting, a former state expert at the Scientific Center for Expertise of Medicinal Products of the Ministry of Health. “The regulation has no effect on this issue. It does not matter at all who will be the holder of the registration certificate, this is a nominal figure who interacts with the authorized bodies. Ownership of the right does not apply to registration procedures, but should be stipulated in the concluded agreement, ”Niyazov summed up.

Coronavirus

Russia Moscow Peace
0 (per day)

Recovered

0

0 (per day)

Got infected

0

0 (per day)

Died

0 (per day)

Recovered

0

0 (per day)

Got infected

0

0 (per day)

Died

0 (per day)

Recovered

0

0 (per day)

Got infected

0

0 (per day)

Died

Source: JHU,
federal and regional
virus control headquarters

Source: JHU, Federal and Regional Anti-Virus Headquarters

Read on RBC Pro

R-Pharm and vaccines

A vaccine against COVID-19, developed by the N.F. Gamaleya is produced directly by the center itself, and Binnopharm is now participating in the production approbation, and, according to the head of the Ministry of Industry and Trade Denis Manturov, from October-November, R-Pharm and Generium will be involved in production. Also Repik’s company has agreement with the Anglo-Swedish corporation “AstraZeneca”, which is developing a vaccine with the University of Oxford – in case of its successful clinical trials, R-Pharm will produce it in Russia and become a hub for the supply of English vaccine to international markets with export to more than 30 countries. “AstraZeneca” received financial support from the UK government and the US Department of Health.

how told businessman on the air of the Dozhd TV channel, the company is also discussing the possibility of producing two more vaccines – Vector and Moscow State University, respectively. “In theory, when we fully deploy our capacities, we will be able to produce a vaccine at Moscow State University and support other Russian projects, including Vector,” Repik concluded in a conversation with RBC. RBC sent a request to the press service of Rospotrebnadzor, whose subordinate institution is the “Vector” center.

The Gamaleya Center explained the principle of administration of the Sputnik V vaccine and placebo

In an interview on Dozhd, Repik explained that in the coronavirus sector, R-Pharm sells two products – Artlegia drugs with the active ingredient olokizumab and Coronavir. “There is a drug [«Коронавир»] in the region of 12 thousand rubles at that stage, so we are talking about about 120 million rubles. revenue. Will this revenue grow? Yes, probably. I think that these numbers can grow five to ten times when the drug gets into the outpatient segment, ”he said.

What is the peculiarity of the MSU vaccine

The MSU vaccine is based on spherical particles that are obtained from the plant tobacco mosaic virus. Proteins from coronaviruses adhere to the surface of these particles. Karpova notes that we are talking about several antigens at once, namely, COVID-19, MERS (Middle East Respiratory Syndrome) and a universal antigen for a number of other coronaviruses that have not yet passed the interspecies barrier from animal to human. Thus, the vaccine being developed by Moscow State University is polyvalent. According to Olga Karpova, this fundamentally distinguishes this development from the vaccines of the Vector Center and the N.F. Gamalei.

“This is a design that is safe for humans; there is no pathogen itself in it. Most likely, the vaccine will be presented in the form of a syringe with a suspension and, most likely, it will be single-dose, ”explains the developer.

LEAVE A REPLY

Please enter your comment!
Please enter your name here